



Global COVID-19 Clinical Platform

NOVEL CORONAVIRUS (COVID-19) - RAPID VERSION

DESIGN OF THIS CASE RECORD FORM (CRF)

This CRF has 3 modules:

Module 1 to be completed on the first day of admission to the health centre.

Module 2 to be completed on first day of admission to ICU or high dependency unit. Module 2 should also be completed daily for as many days as resources allow. Continue to follow-up patients who transfer between wards.

Module 3 to be completed at discharge or death.

GENERAL GUIDANCE

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date.
- Participant Identification Numbers consist of a site code and a participant number. You can obtain a site code and register on the data management system by contacting ncov@isaric.org. Participant numbers should be assigned sequentially for each site beginning with 00001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, you can assign numbers in blocks or incorporate alpha characters. E.g. Ward X will assign numbers from 00001 or A0001 onwards and Ward Y will assign numbers from 50001 or B0001 onwards. Enter the Participant Identification Number at the top of every page.
- Data are entered to the central electronic REDCap database at https://ncov.medsci.ox.ac.uk or to your site/network's independent database. Printed paper CRFs may be used and the data can be typed into the electronic database afterwards.
- Complete every section. Questions marked "If yes,..." should be left blank when they do not apply (i.e. when the answer is not yes).
- Selections with square boxes (□) are single selection answers (choose one answer only).
- Selections with circular boxes (O) are multiple selection answers (choose all that apply).
- Mark 'Unknown' for any data that are not available or unknown.
- Avoid recording data outside of the dedicated areas.
- If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) in the boxes to mark the answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please transfer all paper CRF data to the electronic database. All paper CRFs can be stored by the institution responsible for them. All data should be transferred to the secure electronic database.
- Please enter data on the electronic data capture system at https://ncov.medsci.ox.ac.uk. If your site would like to collect data independently, we can support the establishment of locally hosted databases.
- Please contact us at <u>ncov@isaric.org</u>. If we can help with databases, if you have comments and to let us know that you are using the forms.





MODULE1: complete on admission/enrolment

Site name _	Glasgo)W					Country _	UK				
Date of enr	Date of enrolment [_0_][_9_]/[_0_][_7_]/[_2_][_0_][_0_] CLINICAL INCLUSION CRITERIA											
CLINICAL	INCLU	SION (CRITERIA	l								
Proven or suspected infection with pathogen of Public Health Interest ×Yes □No												
One o	One or more A history of self-reported feverishness or measured fever of ≥ 38 _o C ×Yes □No											
of thes	se		Cough ×Yes □No									
during	this		Dyspnoea (shortness of breath) OR Tachypnoea* ×Yes □No									
illnes	S		Clinical s	uspicior	of ARI	despite	not meeting	criteria abov	/e	□Yes	×No	
* respiratory	⁄ rate ≥50	0 breath	ns/min for <	<1 year; ≥	≥40 for 1	-4 years;	≥30 for 5-12 y	ears; ≥20 for	r≥13 years			
DEMOGRA	APHICS	}										
Sex at Bir	th ×Ma	le □Fe	emale □N	Not spec	ified D	ate of bi	rth [<u>1][</u> 0]/[_0_][_7]/[_1_][_9_][_	8 <u>][</u> 0] If	
date of birt	h is unk	nown,	record: A	ge [0	_][4]	[0 <u></u>]yea	rs OR [_][_]months				
Healthcare	e Worke	er? □Y	'es ×No	□Unkn	own	Labo	ratory Work	er? □Yes	×No □Unknow	n		
Pregnant?	P □Yes	×No	Unkno	wn □N	/A	If yes:	Gestationa	l weeks as	sessment [_]	[] wee	eks	
						(5: 1	"	, ,				
	DATE OF ONSET AND ADMISSION VITAL SIGNS (first available data at presentation/admission)											
]/[_0_][_3_]/[2_][_0_]			
	Admission date at this facility[1][7]/[0][3]/[2][0][2][0]											
_	Temperature [3][8].[9]°C Heart rate [1][0][9]beats/min											
Respirato	ry rate	<u> 1][1</u>	<u>l</u> lbreath	s/min								
BP [1][2][0	_](systo	olic) [<u>0</u>	<u> [8][0</u>	_](dias	tolic) mm	nHg Sever	e dehydra	tion □Yes ×N	o □Unk	nown	
Sternal ca	pillary	refill ti	me >2sec	conds ×	Yes □	No □Unk	nown					
Oxygen sa	aturatio	n: [<u>0</u>][_9_][0_] ⁹	% on ×r	oom air	□oxyge	n therapy □L	Jnknown	AVPU	(circle	one)	
Glasgow (Coma S	core (GCS /15)	[0][9	_]	Maln	utrition □Ye	es×No □U	Inknown			
Mid-upper	arm ci	rcumfe	erence [3][8_	_][5	_]mm H	eight: [1] [8][0]cm Weigh	nt: [0 <u>]</u> [[8][0_]kg
CO-MORBIDITIES (existing prior to admission) (Unk = Unknown)												
Chronic ca		sease		□Yes	×No	□Unk	Diabetes			□Yes	×No	□Unk
Hypertens	ion			□Yes	×No	□Unk	Current sm	oking		□Yes	×No	□Unk
Chronic pu	ılmonar	y disea	se	□Yes	×No	□Unk	Tuberculos	is		□Yes	×No	□Unk
Asthma				□Yes	×No	□Unk	Asplenia			□Yes	×No	□Unk
Chronic kid	dney dis	ease		□Yes	×No	□Unk	Malignant r	neoplasm		□Yes	×No	□Unk
Chronic liv	er disea	se	-	□Yes	×No	□Unk	Other			□Yes	×No	□Unk
Chronic neurological disorder □Yes ×No □Unk If yes, specify: _												
HIV				□Yes-	on ART	□Yes	s-not on ART	×No	□Unknown			

PRE-ADMISSION & CHRONIC MEDICATION

Were any of the following taken within 14 days of admission?

World Health		
Angiotensin cor	PARTICIF nverting enzyme inhibitors (ACE inhibitors)?	PANTIDI1 12 13 14 115 16 117 118 119 11
	eceptor blockers (ARBs)?	□Yes ×No □Unknown
Non-steroidal a	inti-inflammatory (NSAID)?	□Yes ×No □Unknown





PARTICIPANT ID I 1 1 1 2 1 1 3 1 1 4 1 1 5 1 -- 1 6 1 1 7 1 1 8 1 1 9 1

SIGNS AND SYMPTOR	MS ON ADMISSION (Unk :	= Unkno	own)					
History of fever	□Yes □No □Unk	L	ower chest wall indrawing	□Yes	□No	□Unk		
Cough	□Yes □No □Unk	. I	leadache.	□Yes	□No	□Unk		
with sputum produc	tion □Yes □No □Unk	·	Altered consciousness/confu	usion □Yes	□No	□Unk		
with haemoptysis	□Yes □No □Unk		Seizures	□Yes	□No	□Unk		
Sore throat	□Yes □No □Unk		Abdominal pain	□Yes	□No	□Unk		
Runny nose (rhinorrhoea)	. □Yes □No □Unk	١ ١	/omiting / Nausea	□Yes	□No	□Unk		
Wheezing	□Yes □No □Unk		Diarrhoea	□Yes	□No	□Unk		
Chest pain.	□Yes □No □Unk	. (Conjunctivitis	□Yes	□No	□Unk		
Muscle aches (myalgia)	□Yes □No □Unk		Skin rash	□Yes	□No	□Unk		
Joint pain (arthralgia).	□Yes □No □Unk		Skin ulcers	□Yes	□No	□Unk		
Fatigue / Malaise	□Yes □No □Unk		ymphadenopathy	□Yes	□No	□Unk		
Shortness of breath.	□Yes □No □Ur	nk E	Bleeding (Haemorrhage).	□Yes	□No	□Unk		
Inability to walk	□Yes □No □Ur	nk	If bleeding: specify site(s):					
Other □Yes □No □Un	k If yes, specify:					!		
MEDICATION Is the	patient CURRENTLY rece	eiving a	nny of the following?					
Oral/orogastric fluids?	[•] □Yes □No □ Unknown	Intrav	enous fluids? □Yes □N	lo □Unknown				
Antiviral? □Yes □No	□Unknown If yes: ORib	avirin C	Lopinavir/Ritonavir ONe	euraminidase inhib	itor			
•	terferon beta OOther, spec	-						
	s □No □Unknown If yes			Inhaled				
	e agent and maximum daily	y dose:		_ 				
Antibiotic? □Yes □N	o ⊔∪nknown ∃Yes ⊟No ⊟Unknown If			gent? □Yes □No) ⊔Unk	nown		
	☐Yes ☐No ☐Unknown I	-	-					
	ammatory (NSAID) □Yes							
	g enzyme inhibitors (ACE			own				
_	r blockers (ARBs) □Yes [-					
SUPPORTIVE CARE Is the patient CURRENTLY receiving any of the following?								
ICU or High Dependency Unit admission? □Yes □No □Unknown								
Oxygen therapy? □Ye	es 🗆 No 🗆 Unknown If	yes, co	mplete all below					
O ₂ flow : □1-5 L	/min □6-10 L/min □11-15	L/min 🗆]>15 L/min □Unknown					
Source of oxyg	gen: □Piped □Cylinder □0	Concent	rator □Unknown					
Interface: □Na	sal prongs □HF nasal can	nula □N	Mask □Mask with reserve	oir □CPAP/NIV m	ask □l	Jnknown		
Non-invasive ventilation	on? (e.g.BIPAP/CPAP) □Y	′es □No	o □N/A					
	ny)? □Yes □No □ Unknow		Inotropes/vasopress	ors? □Yes □No	□Unkn	nwn		
•) support? □Yes □No □		•			21111		
,	TS ON ADMISSION (*reco		-		KIIOWII			
	,	Not	1	,		Not		
Parameter	Value*	done	Parameter	Value*		done		
Haemoglobin (g/L)			Creatinine (µmol/L)					
WBC count (x109/L)			Sodium (mEq/L)					
Haematocrit (%)			Potassium (mEq/L)					
Platelets (x10 ₉ /L)			Procalcitonin (ng/mL)					
APTT/APTR			CRP (mg/L)					
PT (seconds)			LDH (U/L)					
INR			Creatine kinase (U/L)					
ALT/SGPT (U/L)			Troponin (ng/mL)					
Total bilirubin (µmol/L)			ESR (mm/hr)					
AST/SGOT (U/L)			D-dimer (mg/L)					
Urea (BUN) (mmol/L)			Ferritin (ng/mL)					
Lactate (mmol/L)			IL-6 (pg/mL)					

PARTICIPANT ID I 1 | 1 | 2 | 1 | 3 | 1 | 4 | 1 | 5 | 1 -- 1 | 6 | 1 | 7 | 1 | 8 | 1 | 9 | 1

MODULE 2: follow-up (frequency of completion determined by available resources)

	Date of follow up [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] VITAL SIGNS (record most abnormal value between 00:00 to 24:00)								
,].[]°C Heart rate []		, , , , , , , , , , , , , , , , , , ,	iratory ra	ate [][]bre	athe/min			
	stolic) [][](diasto			_					
			=			11			
Sternal capillary refill time >2seconds □Yes □No □Unknown GCS/15 [][] Oxygen saturation [][
		ш <u>о</u> х,	ygen therapy — enknown		A T T C (officie o	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
DAILY CLINICAL FEATURES (Unk = Unknown)									
Cough □ Yes □ No □ Unk Seizures □ Yes □ No □ Unk and sputum production □ Yes □ No □ Unk Vomiting / Nausea □ Yes □ No □ Unk									
Sore throat									
Chest pain	Chest pain □Yes □No □Unk Conjunctivitis □Yes □No □Unk								
Shortness of breath	□Yes □No □Ur □Yes □No □Ur		lyalgia Other, specify:		□Yes □No □Yes □No	□Unk □Unk			
Confusion LABORATORY RESUL	TS (*record units if differen			_	Lies Livo	ПОПК			
Parameter	Value*	Not	1	Value*		Not			
Parameter	value	done	Parameter	value		done			
Haemoglobin (g/L)			Creatinine (µmol/L)						
WBC count (x109/L)			Sodium (mEq/L)						
Haematocrit (%)			Potassium (mEq/L)						
Platelets (x10 ₉ /L)			Procalcitonin (ng/mL)						
APTT/APTR			CRP (mg/L)						
PT (seconds)			LDH (U/L)						
INR			Creatine kinase (U/L)						
ALT/SGPT (U/L)			Troponin (ng/mL)						
Total bilirubin (µmol/L)			ESR (mm/hr)						
AST/SGOT (U/L)			D-dimer (mg/L)						
Urea (BUN) (mmol/L)			Ferritin (ng/mL)						
	Lactate (mmol/L) □ IL-6 (pg/mL) □ MEDICATION Is the patient CURRENTLY receiving any of the following?								
	Patient CORRENTLY reco								
_	□Unknown If yes: O Riba								
	terferon beta OOther, spec		Lopinavii/Ixitoriavii Orieu	ııaıııııua	Se minibitor				
•	s \square No \square Unknown If yes,	-	Oral Olntravanous Oln	halad					
	e agent and maximum daily								
Antibiotic? □Yes □N	•	_	ifungal agent? □Yes □	 '	rnown				
	⊒Yes □No □Unknown If y				IIIOWII				
	☐Yes ☐No ☐Unknown If								
•	ammatory (NSAID) □Yes		•						
	g enzyme inhibitors (ACE			own					
_	• • •		•						
Angiotensin II receptor blockers (ARBs) □Yes □No □Unknown SUPPORTIVE CARE Is the patient CURRENTLY receiving any of the following?									
ICU or High Dependency Unit admission? □Yes □No □Unknown									
Oxygen therapy? Yes No Unknown If yes, complete all below:									
O ₂ flow volume: □1-5 L/min □6-10 L/min □11-15 L/min □>15 L/min □Unknown									
Source of oxygen: □Piped □Cylinder □Concentrator □Unknown									
Interface: □Nasal prongs □HF nasal cannula □Mask □Mask with reservoir □CPAP/NIV mask □Unknown									
Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □Unknown									
Invasive ventilation (Any)? □Yes □No □Unknown Inotropes/vasopressors? □Yes □No □Unknown									
Extracorporeal (ECMO) support? □Yes □No □Unknown Prone position? □Yes □No □Unknown									
Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown									





PARTICIPANT ID I	- 11	- 11	- 11	- 11	l l	- 11	- 11	- 11	- 1

MODULE 3: complete at discharge/death

DIAGNOSTIC/PATHOGEN TI	ESTING							
Chest X-Ray /CT performed?	? □Yes □No □Unknown If Y	es: infiltrates present? □	Yes □No □Unknown					
<u> </u>	during this illness episode?	-						
	□Negative □Not done If posit i		•					
	Negative □Not done If positive		oV-2 □Other					
	en: □Positive □Negative □Not o							
	: □Positive □Negative □Not don							
_	_		es, specify:					
	•		· · · · · · · · · · · · · · · · · · ·					
-	sitive □Negative □Not done Non-	iaiciparum maiana: 🗆 Posit	ive Linegative Linot done					
HIV: □Positive □Negative □Not done COMPLICATIONS: At any time during hospitalisation did the patient experience:								
•		•	DV: DN: DIL					
Shock	☐Yes ☐No ☐Unknown	Blacking	□Yes □No □Unknown					
Seizure Maningitis/Encophalitia	☐Yes ☐No ☐Unknown☐Yes ☐No ☐Unknown	Bleeding Endocarditis	☐Yes ☐No ☐Unknown ☐Yes ☐No ☐Unknown					
Meningitis/Encephalitis Anaemia	☐Yes ☐No ☐Unknown	Myocarditis/Pericarditis	☐Yes ☐No ☐Unknown					
Cardiac arrhythmia	☐Yes ☐No ☐Unknown	Acute renal injury	□Yes □No □Unknown					
Cardiac arriytiiiia	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown					
Pneumonia	□Yes □No □Unknown	Liver dysfunction	□Yes □No □Unknown					
Bronchiolitis	□Yes □No □Unknown	Cardiomyopathy	□Yes □No □Unknown					
Acute Respiratory Distress	□Yes □No □Unknown	Other	□Yes □No □Unknown					
Syndrome		If Yes, specify						
MEDICATION: While hospita	lised or at discharge, were an	y of the following adminis	tered?					
Oral/orogastric fluids? □Yes	S □No □Unknown Intravenou	us fluids? □Yes □No □Un	known					
Antiviral? □Yes □No □Uni	known If yes: ORibavirin OLo	pinavir/Ritonavir O Neuramir	nidase inhibitor					
O Interferon alpha	OInterferon beta OOther, speci	ify:						
Antibiotic? □Yes □No □U	nknown If yes, specify:							
Corticosteroid? □Yes □No	□Unknown If yes, route: ○ ○	ral OIntravenous OInhaled	j					
If ves. specify agent and ma	aximum daily dose:							
1	No □Unknown If yes, specify:							
	□No □Unknown If yes, specif							
	□No □Unknown If yes , speci							
		•	_					
Non-steroidal anti-inflammatory (NSAID)								
SUPPORTIVE CARE: At ANY time during hospitalisation, did the patient receive/undergo:								
ICU or High Dependency Unit admission? □Yes □No □ Unknown If yes, total duration:days								
Date of ICU admission:[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □N/A								
	ge:[_D_][_D_]/[_M_][_M_]/[_2_]		outcome □N/A					
	yo. □Unknown If yes, comple		days					
, ,,	•		uayo					
O ₂ flow volume: O1-5 L/min O6-10 L/min O11-15 L/min O>15 L/min Source of oxygen: OPiped OCylinder OConcentrator								
1	•	Mack with reconvoir OCDA	D/NIIV mask					
, ,	Interface: ONasal prongs OHF nasal cannula OMask OMask with reservoir OCPAP/NIV mask							
Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □ Unknown If yes, total duration:days								
Invasive ventilation (Any)? □Yes □No □Unknown If yes, total duration:_days								
Extracorporeal (ECMO) support? Yes No Unknown If yes, total duration: days								
Prone position? ☐ Yes ☐ No ☐ Unknown If yes, total duration:days								
Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown								
Inotropes/vasopressors? □Yes □No □Unknown If yes, total duration:days								
OUTCOME								
Outcome: □Discharged alive □Hospitalized □Transfer to other facility □Death □Palliative discharge □Unknown								
Outcome date: D D / M M / 2 D O V D O O O O O O O O O O O O O O O O								
If Discharged alive: Ability to self-care at discharge versus before illness: □Same as before illness □Worse □Better □Unknown								